Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27713605 | 0.77 | ADCY10 (0.38) | NR1H2NR1H3CDK1RXFP1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL26694486 | 0.68 | KDR (0.41) | NR1H2NR1H3ALDH1A1 | |
| SCHEMBL3963652 | 0.68 | CTSK (0.38) | NR1H2NR1H3ALDH1A1 | |
| SCHEMBL12676870 | 0.67 | L3MBTL1 (0.49) | ALDH1A1GAA | |
| SCHEMBL9741525 | 0.65 | RORC (0.38) | ALDH1A1GAA | |
| SCHEMBL2387153 | 0.65 | SLC22A12 (0.46) | ALDH1A1 | |
| SCHEMBL27408304 | 0.64 | TP53 (0.42) | ALDH1A1 | |
| SCHEMBL3261698 | 0.64 | SMN1; SMN2 (0.41) | ALDH1A1 | |
| SCHEMBL17450621 | 0.64 | MAPT (0.45) | — | |
| SCHEMBL13495143 | 0.64 | SLC5A2 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841430-A4 | SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1841430-A2 | SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081388-A2 | SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | PIGS, HRH4, GPR68 | NR1H2 1077/4885NR1H3 1135/4885TRPA1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.